Dr Carl Firth is Founder and CEO of ASLAN Pharmaceuticals, an Asia enabled pharmaceutical company that develops novel medicines for global markets. Previously, he was Head of Asia Healthcare at Bank of America Merrill Lynch, supporting public and private financing of healthcare companies across the region and advising on M&A transactions.
Prior to joining the banking industry, he worked for AstraZeneca for nearly 10 years. In 2007, he was the Regional Business Development Director, AsiaPac, and a member of the regional management team. From 2004-6, Carl led new product development and business development in AstraZeneca China, based in Shanghai, where he was responsible for the development of new products for the China market and local inlicensing activities.
Carl has held positions in other commercial areas in the UK, including acquisitions, licensing and competitive intelligence, and has over 5 years of pharmaceutical R&D experience.
Carl holds a PhD from Cambridge University in Molecular Biology (Trinity College), an Executive MBA from London Business School and a degree in Molecular Biology from Cambridge University.